Latest Safety News

Lynas Rare Earths posted a record A$288.9 million in quarterly sales for Q4 FY26, driven by higher prices and heavy rare earth sales. The company advanced its Malaysia heavy rare earth facility despite a cost surge and appointed Pol Le Roux as interim CEO.

Cambium Bio has raised just over A$1 million through a strategic placement at a 17% premium, boosting a key shareholder’s stake as it advances its pivotal Phase 3 trial for dry eye disease.

Paladin Energy completes Langer Heinrich Mine ramp-up, delivering strong FY2026 results and advancing its Canadian PLS Project with a new uranium discovery. FY2027 guidance forecasts stable production and costs amid ongoing regulatory progress.

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.

Optiscan Imaging has kicked off a US clinical trial with Mayo Clinic to test its InVue and InForm devices in breast conserving surgery, aiming to generate data for FDA 510(k) submissions and validate a new surgical-pathology workflow.

Radiopharm Theranostics reported robust Phase 2b results for RAD101 in brain metastases imaging, hitting 93% concordance with MRI and setting the stage for a U.S. Phase 3 trial. Meanwhile, its Phase 1 trial of RAD204 showed durable partial responses and good tolerability in advanced solid tumors.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its Phase 1b trial of PYC-003 for Polycystic Kidney Disease, alongside regulatory clearance for an Open-Label Extension allowing continuous dosing up to 24 months.

Antares Metals (ASX: AM5) has secured approval to begin heritage surveys and drilling at its Quinns VMS project in Western Australia, backed by $237,500 in government co-funding. The company aims to test high-grade extensions of the historic Austin deposit and untested regional prospects, with copper prices rising sharply since the last resource estimate.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

Biotron has received pivotal regulatory feedback from the European Medicines Agency ruling out a Hybrid Marketing Authorisation for SedRx, prompting plans for pivotal clinical trials. The company also advances its lead antiviral candidate BIT-HBV001 against Hepatitis Delta Virus and appoints a new chairman.

New Murchison Gold Limited's Crown Prince Gold Mine sustained robust production with 15,455 ounces sold in the June quarter, while the Garden Gully Gold Project’s resource estimate jumped 47% to 359,000 ounces. Mining has now commenced at the Cloudkicker open pit, supporting growth and operational flexibility.

Hillgrove Resources boosted copper production and cash flow in the June quarter, hitting a 1.8Mtpa run rate at Kanmantoo and securing approval for the Emily Star underground development.